RELMADA THERAPEUTICS INC (RLMD) Stock Analyst Earnings Estimates
NASDAQ:RLMD - Nasdaq - US75955J4022 - Common Stock - Currency: USD
Full estimates are only available for subscribed users, you can see which data is available below.
Subscribed users also see more surprise data, now it is restricted to 4 quarters.
Examples of complete estimate data are available for MSFT and AAPL.
Registered users have access to more data. Please register or login for additional estimates and surprises .
| 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | N/A | N/A | N/A | N/A -100.00% | N/A | N/A | N/A | |||||||||||
| EBITDA YoY % growth | -12.95M | -17.09M -31.97% | -16.17M 5.38% | -7.13M 55.91% | -6.92M 2.95% | -12.73M -83.96% | -60.84M -377.93% | -125.7M -106.61% | -161.25M -28.28% | N/A 34.29% | N/A 15.94% | N/A -18.54% | N/A -20.77% | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -12.95M | -17.1M -32.05% | -16.22M 5.15% | -7.22M 55.49% | -6.92M 4.16% | -12.73M -83.96% | -60.84M -377.93% | -125.7M -106.61% | -161.25M -28.28% | -103.702M 35.69% | N/A 13.51% | N/A 9.40% | N/A -22.80% | N/A 14.96% | N/A -3.97% | N/A -4.05% | N/A -4.44% | |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EPS YoY % growth | N/A | N/A | N/A 92.46% | N/A | N/A | N/A | N/A | -7.14 -93.19% | -5.45 23.67% | -3.28 39.82% | N/A 14.82% | N/A 58.15% | N/A -41.03% | N/A 49.28% | N/A 12.20% | N/A 12.50% | N/A 11.11% |
All data in USD
| Q4 / 24 | Q1 / 25 | Q2 / 25 | Q3 / 25 | Q4 / 25 | |
|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.71 15.18% | -0.32 56.08% | -0.26 56.78% | -0.12 83.57% | -0.06 91.62% |
| Revenue Q2Q % growth | |||||
| EBITDA Q2Q % growth | N/A | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -23.307M 13.13% | -18.156M 21.02% | -16.116M 14.36% | -14.076M 38.82% | -12.036M 48.36% |
All data in USD
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q3 2024 Q2Q % growth | -0.72 1.37% | -0.65 | -0.07 | -10.12% |
| Q2 2024 Q2Q % growth | -0.59 29.76% | -0.84 | 0.25 | 30.01% |
| Q1 2024 Q2Q % growth | -0.72 17.24% | -0.87 | 0.15 | 16.90% |
| Q4 2023 Q2Q % growth | -0.84 40.43% | -0.85 | 0.01 | 0.78% |
| Q3 2023 Q2Q % growth | -0.73 44.27% | -0.93 | 0.20 | 21.61% |
| Q2 2023 Q2Q % growth | -0.84 36.84% | -0.91 | 0.07 | 8.17% |
| Q1 2023 Q2Q % growth | -0.87 37.86% | -0.91 | 0.04 | 4.08% |
| Q4 2022 Q2Q % growth | -1.41 21.67% | -1.35 | -0.06 | -4.12% |
| Q3 2022 Q2Q % growth | -1.31 46.31% | -1.48 | 0.17 | 11.40% |
| Q2 2022 Q2Q % growth | -1.33 14.74% | -1.30 | -0.03 | -2.42% |
| Q1 2022 Q2Q % growth | -1.40 -4.48% | -1.29 | -0.11 | -8.45% |
| Q4 2021 Q2Q % growth | -1.80 -37.40% | -1.87 | 0.07 | 3.57% |
| Q3 2021 Q2Q % growth | -2.44 -132.38% | -1.63 | -0.81 | -49.82% |
| Q2 2021 Q2Q % growth | -1.56 -113.70% | -1.50 | -0.06 | -3.81% |
| Q1 2021 Q2Q % growth | -1.34 -212.79% | -1.42 | 0.08 | 5.78% |
| Q4 2020 Q2Q % growth | -1.31 -256.75% | -1.18 | -0.13 | -10.84% |
| Q3 2020 Q2Q % growth | -1.05 | -0.88 | -0.17 | -19.01% |
| Q2 2020 Q2Q % growth | -0.73 | -0.60 | -0.13 | -22.34% |
| Period | Reported | Estimate | Difference | Surprise |
|---|
| Next Q (1 month) | Next Q (3 month) | Next Year (1 month) | Next Year (3 month) | |
|---|---|---|---|---|
| EPS | -15.9% | -15.9% | 0% | -3.38% |
| Revenue | N/A | N/A | N/A | N/A |